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INTRODUCTION 
 
      Various reports have described an association between gel-based intravascular volume 
expanders and an increased propensity for coagulopathy and postoperative haemorrhage.  We 
sought to determine whether the use of these intravenous fluids was associated with increased 
bleeding complications in patients undergoing cardiac surgery with cardiopulmonary bypass.  
 
METHODS 
 
      A comprehensive retrospective review was undertaken of all patients who underwent 
cardiac surgery with cardiopulmonary bypass at our institution between January and July 2005.  
Routine use of gel-based colloid volume expanders (Gelofusine, Vifor Medical SA, Switzerland) 
in the perioperative period was discontinued in June 2005.  Postoperative surgical drainage, 
requirements for blood products, and incidence of re-operation to secure haemostasis was 
recorded in those patients who received gelofusine during the perioperative period, and 
compared with those patients who did not receive any gelofusine.  Biochemical markers of 
coagulation status were also compared between the two patient groups.   
 
RESULTS 
 
      During the review period, 190 patients underwent cardiac surgery via full median sternotomy 
with cardiopulmonary bypass.  One hundred and twenty-eight patients received intravenous 
volume expansion with gelofusine during the perioperative period, as compared with 62 patients 
who received alternate intravascular fluid supplementation.  Mean postoperative bleeding was 
significantly greater in the gelofusine group than in the non-gelofusine group at six hours after 
surgery (520 +/- 325 mls vs. 340 +/- 195 mls, p < 0.001), and at removal of the surgical drains 
(1384 +/- 817 mls vs. 981 +/- 498 mls, p = 0.001).  Twelve patients in the gelofusine group 
(9.4%) required re-operation to secure haemostasis, as compared with zero patients in the non-
gelofusine group.  More patients who received gelofusine required administration of some type 
of blood product in the perioperative period than those patients who did not receive gelofusine 
(68.8% vs. 33.9%, p < 0.001), including red blood cells (65.6% vs. 33.9%, p < 0.001), platelets 
(14.1% vs. 1.6%), cryoprecipitate (19.5% vs. 3.2%), and fresh frozen plasma (4.7% vs. 0%).  
Immediate postoperative platelet count was significantly lower in the gelofusine group than in 
the non-gelofusine group (p = 0.022), as was the fibrinogen level (p = 0.033).   
 
DISCUSSION 
 
       The use of gel-based colloid volume expanders in patients undergoing cardiac surgery with 
cardiopulmonary bypass is associated with increased bleeding complications and a concomitant 
greater requirement for transfusion of blood products.  We suggest that alternate intravenous 
fluids be administered to such patients when intravascular volume supplementation is required 
in the perioperative period. 
